Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Immunotherapy in Thoracic Oncology: Incredible Progress and Remaining Challenges
share announcement

Immunotherapy in Thoracic Oncology: Incredible Progress and Remaining Challenges

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (1 December 2022) | Viewed by 5211

Special Issue Editors

Dr. Dwight H. Owen

E-Mail Website
Guest Editor
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center – James Comprehensive Cancer Center, 1800 Cannon Drive, Suite 1240, Columbus, OH 43210, USA
Interests: biomarkers and novel immunotherapy strategies to overcome resistance in NSCLC
Dr. Greg Durm

E-Mail Website
Guest Editor
Division of Hematology/Oncology, Department of Medicine, IU School of Medicine, Indianapolis, IN, USA
Interests: ICI in resectable; locally advanced NSCLC

Special Issue Information

Dear Colleagues,

This Special Issue will focus on the significant progress in the treatment of thoracic cancers in recent years, including reviews of the new standard of care for lung cancer as well as rarer cancers such as  mesothelioma and thymic neoplasms. Just as important are the challenges that remain to be overcome. In this issue, we will focus on treatment of patients with NSCLC in second line and beyond, use of ICI in patients with earlier-stage NSCLC, the unique pharmacology of ICI, the role of ICI in elderly patients with NSCLC and other thoracic cancers, the optimization of first- and second-line treatment for patients with small cell lung cancer, and the selection of chemotherapy or immunotherapy for patients with mesothelioma and thymic neoplasms. We will also address areas of ongoing research including immune toxicities and attempts to overcome resistance to ICI.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Dwight H. Owen
Dr. Greg Durm
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immune checkpoint inhibitors (ICI)
  • immune checkpoint blockade (ICB)
  • programmed-death 1 (PD-1)
  • non-small cell lung cancer (NSCLC)
  • lung cancer
  • thoracic oncology
  • biomarkers
  • clinical trials

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2371 KiB  
Article
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts
by Christos Chouaid, Michael Thomas, Didier Debieuvre, Isabelle Durand-Zaleski, Stefan Zacharias, Lise Bosquet, Annika Groth, Annette Fleitz, Alan Calleja, Sonya Patel, Laure Lacoin, Melinda J. Daumont, John R. Penrod, Robert Carroll, Daniela Waldenberger, François-Emery Cotté, Clarisse Audigier-Valette and Frank Griesinger
Cancers 2022, 14(24), 6148; https://doi.org/10.3390/cancers14246148 - 13 Dec 2022
Viewed by 2410
Abstract
This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in second-line or later (2L+) in France and Germany between 2015 and 2020. Patients with aNSCLC (stage IIIB–C/IV) receiving nivolumab in 2L+ were [...] Read more.
This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in second-line or later (2L+) in France and Germany between 2015 and 2020. Patients with aNSCLC (stage IIIB–C/IV) receiving nivolumab in 2L+ were included from the retrospective Epidemiological Strategy and Medical Economics of Advanced and Metastatic Lung Cancer cohort (ESME-AMLC, France; 2015–2019) and Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP, Germany; 2016–2020). Overall, 2262 ESME-AMLC and 522 CRISP patients were included. Median treatment duration (95% confidence intervals) was 2.8 months (2.5–3.2) in squamous and 2.5 months (2.3–2.8) in non-squamous/others patients in ESME-AMLC, and 2.3 months (1.4–3.1) and 2.3 months (2.0–2.8), respectively in CRISP. One-year and two-year overall survival (OS) were 47.2% and 26.7% in squamous and 50.8% and 32.8% in non-squamous/others patients in ESME-AMLC, and 43.1% and 20.9%, and 37.7% and 18.9%, respectively in CRISP. Poorer performance score and shorter time from start of previous line of therapy initiation were significantly associated with shorter treatment duration and OS. This study confirms, in real-world clinical databases, the efficacy of nivolumab previously observed in clinical trials. Full article
(This article belongs to the Special Issue Immunotherapy in Thoracic Oncology: Incredible Progress and Remaining Challenges)
►▼ Show Figures

Figure 1

13 pages, 6562 KiB  
Article
Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
by Sue Youn Kim, Tae-Eun Kim, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, Hyo Rim Kim, In Sook Woo and Tae-Jung Kim
Cancers 2022, 14(13), 3138; https://doi.org/10.3390/cancers14133138 - 27 Jun 2022
Cited by 1 | Viewed by 2455
Abstract
PD-L1 harmonization studies revealed a strong correlation between the 22C3 and SP263 assays in non-small-cell lung cancer (NSCLC). However, the assays’ characteristics have yet to be validated in a variety of clinical and analytical settings. The results of 431 NSCLC samples tested concurrently [...] Read more.
PD-L1 harmonization studies revealed a strong correlation between the 22C3 and SP263 assays in non-small-cell lung cancer (NSCLC). However, the assays’ characteristics have yet to be validated in a variety of clinical and analytical settings. The results of 431 NSCLC samples tested concurrently in routine clinical practice with the PD-L1 22C3 and SP263 assays were reviewed, and both assays were performed on 314 archives of surgically resected NSCLCs to assess PD-L1 expression in relation to variables such as FFPE block age and FFPE section storage condition. In routine clinical samples, 22C3 showed the highest concordance rate with 94.5% of SP263 tumor proportion score (TPS) ≥50% and 92.3% of SP263 TPS ≥1%, while SP263 showed a concordance rate with 79.6% of 22C3 TPS ≥50% and 89.9% of 22C3 TPS ≥1%. In the archival analysis, the high TPS of 22C3 and SP263 (versus TPS 1%) were significantly associated with a more recent block (<3 years versus ≥3 years) (p = 0.007 and p = 0.009, respectively). Only the TPS of 22C3 was reduced when FFPE sections were stored at room temperature compared to SP263. However, when stored at 4 °C, the storage duration had no effect on expression in either assay. For 22C3 TPS 1–49 percent and ≥50 percent (OR = 1.73, p = 0.006 and OR = 1.98, p = 0.002, respectively). There was a considerably larger chance of preserved 22C3 expression in recent room-temperature paraffin section storage, although SP263 demonstrated preserved expression in prolonged room-temperature section storage. Despite the good association between PD-L1 22C3 and SP263 in routine clinical samples, FFPE blocks older than 3 years and sections held at room temperature for more than 1 week may result in an underestimation of PD-L1 status, particularly for the 22C3 test. However, the SP263 assay was more sensitive under these conditions. Full article
(This article belongs to the Special Issue Immunotherapy in Thoracic Oncology: Incredible Progress and Remaining Challenges)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop